News and Press Releases
Press releases
Theralase® Granted Canadian Anti-Cancer Patent
Press ReleaseTheralase® Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them Toronto, Ontario – November 15, 2018 Theralase Technologies Inc. (“Theralase®” or the “Co...
Theralase® Release 3Q2018 Financial Statements
Press ReleaseToronto, Ontario – November 29, 2018 “Theralase®” or the “Company” (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PD...
Patient Five Cancer-Free After Single PDT Treatment
Press ReleaseTheralase® Provides Update on 9 months Post Treatment Cystoscopy Analysis Toronto, Ontario – November 8, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceut...
Theralase® Announces Completion of Non-Brokered Private Placement for Approximately $1.1 million
Press ReleaseToronto, Ontario – October 3, 2018 Theralase Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (th...
Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System
Press ReleaseTheralase® Affiliated Researchers Present New Data that Demonstrates the Application of Theralase’s Lead Photo Dynamic Compound, TLD-1433, in the Destruction of Gastrointestinal Dysplasia and Esophageal Cancer. Toronto, Ontario – O...
Health Canada Approves Commencement of Phase II Clinical Study
Press ReleaseToronto, Ontario – September 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated...
Theralase’s® Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy
Press ReleaseTheralase® Researchers Invited to Present at International Conference in Germany Toronto, Ontario – September 4, 2018 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage phar...
Theralase® Announces Proposed Non-Brokered Private Placement of up to $10 Million
Press ReleaseNot for distribution to U.S. news wire services or dissemination in the United States. Toronto, Ontario – August 28, 2018 Theralase Technologies Inc. (the “Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage p...
Theralase® Provides Corporate Update
Press ReleaseTheralase® Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study Toronto, Ontario – August 27, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTC...
Theralase® Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval
Press ReleaseToronto, Ontario – August 20, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
